Medical Advocates
ARV/HAART
  Switching Therapy 
              
General Reports 
 Switching from PI-Based Therapy
 Treatment Failure Predictors   








 
 
HAART Main Page Main New/Newsworthy Home Page      
Last Update:  October 14, 2008  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 
General Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
A WEEK IN REVIEW FEATURED REPORT
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy
and regimen modification.
Petersen ML, van der Laan MJ, Napravnik S, et al
AIDS. 2008 Oct 18;22(16):2097-106.
Abstract
 
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy:
multicentre cohort study.
United Kingdom Collaborative HIV Cohort Study
AIDS. 2008 Oct 1;22(15):1943-50.
 Abstract
 
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M, O’Brien D,  et al
AIDS. 2008 Jul 11;22(11):1305-12.
Abstract
 
Relationships between drug exposure, changes in metabolic parameters and body fat in
HIV-infected patients switched to a nucleoside sparing regimen.
 Autar RS, Boyd MA, Wit FW, et al
Antivir Ther. 2007;12(8):1265-71.
 Abstract
 
Successive switching of antiretroviral therapy is associated with high psychological and
physical burden.
Sherr L, Lampe F, Norwood S, et al
Int J STD AIDS. 2007 Oct;18(10):700-4.
 Abstract 
 
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys E, Hernandez L, Rutherford G. et al
Cochrane Database Syst Rev. 2007 Oct 17;
 Abstract 
 
A WEEK-IN-REVIEW FEATURED REPORT
Early Modification of Initial HAART Regimen Associated with Poor Clinical Outcome in HIV
Patients
 Park WB, Choe PG, Kim SH, et al 
AIDS Res Hum Retroviruses. 2007 Jun;23(6):794-800
 Abstract 
 
Changing antiretroviral therapy in the setting of virologic relapse: review of the current
literature.
Anderson AM, Bartlett JA.  
Curr HIV/AIDS Rep. 2006 May;3(2):79-85..
 Abstract
 
Antiretroviral therapy of VIH infection: duration and reasons for changing the first therapeutic
regimen in 518 patients.
Gratacos L, Tuset M, Codina C, et al 
Med Clin (Barc). 2006 Feb 25;126(7):241-5.
 Abstract

Starting or changing therapy – a prospective study exploring antiretroviral decision-
making.
Fehr JS, Nicca D, Sendi P, et al  Infection. 2005 Aug;33(4):249-56.
Abstract
 
Switch strategies in patients on effective HAART.
 Maggiolo F, Ripamonti D, Suter F.
 J Antimicrob Chemother. 2005 Apr 22;
 Abstract
 
What’s next? Treatment options when the first antiretroviral regimen fails virologically
or is not tolerated, Part 2.
 Ruane PJ, Daar ES. 
AIDS Read. 2004 Sep;14(9):487-98.
Abstract
 
What’s next? Treatment options when the first antiretroviral regimen fails virologically or is
not tolerated, Part 1.
Ruane PJ, Daar ES.
AIDS Read. 2004 Aug;14(8):421-6, 431-2, 434.
 Abstract

Perspectives on HAART: switch maintenance therapy.
 Leen CL.
 Int J STD AIDS. 2003 Sep;14(9):577-82
Abstract

Switching effective antiretroviral therapy: a review.
 Drechsler H, Powderly WG.
 Clin Infect Dis. 2002 Nov 15;35(10):1219-30
 Abstract
Radata – implementation of resistance analysis and expert advice for optimized HAART
switches in general practice of HIV-infected individuals via a compiling internet presence.
Paech V, Lorenzen T, Stoehr A, Plettenberg A.
Eur J Med Res. 2002 Jul 24;7(7):323-9
 Abstract

Switch studies: a review.
Murphy RL, Smith WJ.
HIV Med. 2002 Apr;3(2):146-55.
 Abstract
 
Prevalence and correlates of highly active antiretroviral therapy switching in the
Women’s Interagency HIV Study.
Kirstein LM, Greenblatt RM, Anastos K, et al
J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):495-503.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
The Use and Response to Second Combination ART Regimens in EuroSIDA
A Cozzi-Lepri, M Cunnington, A Lazzarin,  et al
 (15 CROI)
 Abstract

Reasons for switching highly active antiretroviral therapy (HAART) regimens among
HIV/AIDS patients in low-resource settings: the case of Mbagathi District Hospital,
Kenya
 Kocholla L, Wangai M, Kusu N,. et al
 (4th IAS Conference)
 Abstract

POSTER
 A Randomized Pilot Study of Delayed ART Switch in Subjects with Detectable Viremia
on HAART
S Riddler, H Jiang, S Deeks, et al
 (13  CROI)
 PDF Poster     Abstract
 
Switching from PI-Based Regimens
 

     Journal Papers, Abstracts, and Commentaries

  Improvement of HAART-associated insulin resistance and dyslipidemia after replacement
of protease inhibitors with abacavir.
 Walli RK, Michl GM, Bogner JR, Goebel FD.
 Eur J Med Res. 2001 Oct 29;6(10):413-21
 Abstract
 
Time to discontinuation of the first highly active antiretroviral therapy regimen: a
comparison between protease inhibitor- and non-nucleoside reverse transcriptase
inhibitor-containing regimens.
 Dorrucci M, Pezzotti P, Grisorio B, et al
 AIDS. 2001 Sep 7;15(13):1733-6.
 Abstract
 
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year
prospective observational study.
 Manfredi R, Chiodo F.
 Int J STD AIDS. 2001 Feb;12(2):84-8
Abstract
 
Switching from a PI-based to a PI-sparing regimen for management of metabolic or
clinical fat redistribution.
 Moyle G, Baldwin C.
 AIDS Read. 2000 Aug;10(8):479-85.
 Abstract
 
Treatment Failure Predictors
 
     Journal Papers, Abstracts, and Commentaries
 
  Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
 Masuhr A, Mueller M, Simon V, et al
 Eur J Med Res. 2002 Aug 30;7(8):341-6.
 Abstract 
 
 
Extent of human immunodeficiency virus type 1 drug resistance as a predictor of
virological ailure after genotype-guided treatment switch.
Dionisio D, Vivarelli A, Zazzi M, et al.
Clin Infect Dis. 2001 Sep 1;33(5):706-9.
 Abstract
 

HAART Main Page   Home Page      

Switching Therapy